What Fedora Pharmaceuticals does

Fedora Pharmaceuticals Inc. is a privately-held, Edmonton-based clinical-stage biopharmaceutical company founded in 2011 that discovers and develops novel antibiotics targeting antimicrobial resistance (AMR). The company focuses on multidrug-resistant Gram-negative infections, with particular emphasis on the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) identified by the WHO as the most critical unmet needs in infectious disease. Its end users are hospital patients with complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, and community-acquired infections such as drug-resistant gonorrhea — settings where existing beta-lactam antibiotics are failing.

The company's pipeline is anchored by two structurally differentiated candidates. Nacubactam is a Phase 3-ready beta-lactamase inhibitor that works through multiple mechanisms, inhibiting both beta-lactamase enzymes and certain bacterial cell wall enzymes, and is being co-developed with Meiji Seika as a combination product with meropenem for complicated urinary tract and severe respiratory tract infections including CRE and meropenem-resistant strains. FPI-2119 is a first-in-kind derivative of the lactivicin class — a non-beta-lactam antibiotic that targets penicillin-binding proteins (PBP1a, 1b, 2, and 3) without a beta-lactam scaffold, thereby bypassing the beta-lactamase resistance mechanism that has eroded the effectiveness of drugs such as cefepime. Preclinical data demonstrate bactericidal activity against Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacterales, E. coli, Klebsiella pneumoniae, and resistant Neisseria gonorrhoeae, with dose-dependent reductions in bacterial burden in murine cUTI models and a clean off-target safety profile supporting BID or QD dosing. Fedora retains key US rights to nacubactam and is actively pursuing a US development partner.

Fedora operates as a pre-commercial biotech under a licensing and partnership revenue model. The company is privately held with no disclosed institutional equity funding; visible capital inflows total approximately $396K across two 2012-2013 tranches that resemble grants or non-dilutive capital. With a team of 1-10 employees led by founder/CEO Christopher G. Micetich and CSO Sameeh M. Salama, Ph.D., the company monetizes its pipeline through licensing deals (e.g., Meiji Seika for nacubactam) and is actively soliciting additional industry and academic partnerships. Scientific outreach is conducted through peer-reviewed conferences (ESCMID Global, Interdisciplinary Meeting on AMR), press releases, and a Scientific Advisory Board anchored by recognized authorities in beta-lactam and resistance biology.

Name

Fedora Pharmaceuticals

Legal name

Fedora Pharmaceuticals Inc.

Website

https://fedorapharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Fedora Pharmaceuticals is a privately-held Edmonton biotech developing novel antibiotics to combat antimicrobial resistance. Its pipeline includes the Phase 3-ready beta-lactamase inhibitor nacubactam, partnered with Meiji Seika, and the preclinical lactivicin derivative FPI-2119, both targeting multidrug-resistant Gram-negative pathogens.

Ownership category

akta.pro rank

Product category

Infectious Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Antimicrobial drug discovery
• Antibiotic development
• Beta-lactamase inhibitors
• Antimicrobial resistance therapeutics
• Preclinical antibiotic research

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Partnership Agreements: Fedora Pharmaceuticals generates revenue through licensing its drug candidates to larger pharmaceutical partners and through development partnerships. The company holds key US rights to nacubactam and is seeking licensing as a combination product with meropenem. They are actively pursuing business development opportunities including partnerships and licensing agreements with industry and academia.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Fedora Pharmaceuticals discovers and develops proprietary small-molecule antibiotic candidates that address antimicrobial resistance, primarily against multidrug-resistant Gram-negative pathogens. Its two lead assets are FPI-2119, a first-in-kind non-beta-lactam lactivicin derivative targeting penicillin-binding proteins, and Nacubactam, a Phase 3-ready beta-lactamase inhibitor designed to be combined with meropenem. The company commercializes these candidates through licensing and co-development partnerships with larger pharmaceutical companies rather than selling products directly.

Product overview

Fedora Pharmaceuticals is a privately-held biotech founded in 2011, headquartered in Edmonton, Alberta, Canada, dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance. The company has two main pipeline candidates: Nacubactam (Phase 3-ready beta-lactamase inhibitor) and FPI-2119 (first-in-kind lactivicin derivative in preclinical development). Nacubactam works by inhibiting beta-lactamases to restore activity of existing beta-lactam antibiotics, while FPI-2119 bypasses the beta-lactamase problem entirely with a structurally distinct non-beta-lactam mechanism targeting penicillin-binding proteins.

Differentiator

Problem solved

Functional benefit

Products and services

• FPI-2119 First-in-kind non-beta-lactam derivative of the lactivicin class targeting penicillin-binding proteins (PBP1a, 1b, 2, 3) for the treatment of multidrug-resistant Gram-negative infections including hospital-acquired pneumonia, complicated urinary tract infections, and complicated intra-abdominal infections caused by ESKAPE pathogens and drug-resistant Neisseria gonorrhoeae.
• Nacubactam Phase 3-ready beta-lactamase inhibitor that uses multiple mechanisms of action to inhibit beta-lactamase enzymes and certain bacterial cell wall enzymes; intended for use in combination with beta-lactam antibiotics such as meropenem to treat complicated urinary tract infections, severe respiratory tract infections, and carbapenem-resistant Enterobacterales (CRE) infections.

Quantifiable outcome

• Dose-dependent bactericidal activity against Pseudomonas aeruginosa with low frequency of resistance emergence
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered significant and core.

• St. Jude Children's Research HospitalsignificantStrategic or Co-development Partner · 1 April 2026Collaborative research partnership on FPI-2119 development. Researchers at St. Jude, including Dr. Alaa Sayed, conducted mechanistic studies demonstrating that FPI-2119 binds multiple essential PBPs (PBP1a, 1b, 2, and 3) in E. coli and Klebsiella pneumoniae, supporting a multi-target mechanism that may help limit the emergence of resistance.
• JMI Laboratories (Part of Element)significantStrategic or Co-development Partner · 1 April 2026Collaborative research partner contributing to in vitro activity testing of FPI-2119 against multidrug-resistant clinical isolates at JMI Laboratories as part of the Element organization.
• Indiana UniversitysignificantStrategic or Co-development Partner · 1 April 2026Academic collaboration with researchers including Dr. Karen Bush, Professor of Practice in the Department of Biotechnology. Dr. Bush conducted resistance frequency and beta-lactamase activity studies for FPI-2119.
• Pharmacology Discovery Services (Eurofins Discovery Partner Lab)significantStrategic or Co-development Partner · 1 April 2026Contract research partner that conducted in vivo efficacy studies in animal infection models, including murine bloodstream infection and pneumonia models for FPI-2119. Dr. Lynn Miesel served as senior technical director.
• Meiji SeikacoreStrategic or Co-development PartnerMeiji Seika is a key partner advancing nacubactam, a Phase 3-ready beta-lactamase inhibitor. This partnership focuses on developing nacubactam as a combination product with meropenem for the treatment of complicated urinary tract and severe respiratory tract infections including those caused by meropenem-resistant strains and CRE infections.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Entasis Therapeutics: Developed durlobactam (a beta-lactamase inhibitor for A. baumannii infections) and was acquired by Innoviva in 2022. Directly comparable as a small-cap infectious disease biotech focused on beta-lactamase inhibitor combinations against WHO priority Gram-negative pathogens.
• Paratek Pharmaceuticals: Developed and commercialized omadacycline (Nuzyra), a novel tetracycline antibiotic for community-acquired pneumonia and skin infections, and was acquired by Gurnet Point and Novo Holdings in 2023. Comparable as a developer of innovative antibiotics addressing resistant infections.
• VenatoRx Pharmaceuticals: Developed cefepime-taniborbactam, a beta-lactamase inhibitor combination targeting CRE infections, in a deal structure with Everest Medicines/Shionogi. Closely mirrors Fedora's nacubactam-meropenem program in mechanism, indication, and stage of development.
• Iterum Therapeutics: Developed sulopenem, an oral penem antibiotic for uncomplicated and complicated UTIs caused by resistant pathogens. Comparable as a small-cap antibiotics developer with a focus on resistant UTI indications aligned with Fedora's cUTI target market.
• Qpex Biopharma: Developed xeruborbactam, a beta-lactamase inhibitor for resistant Gram-negative infections, and was acquired by Shionogi in 2023. Highly comparable small biotech in the same BLI therapeutic class with similar partnership-driven exit trajectory.
• Spero Therapeutics: Developed tebipenem HBr and SPR206, antibiotics targeting multidrug-resistant Gram-negative pathogens. Comparable as a small public infectious disease biotech with similar licensing and partnership economics in the AMR space.
• Melinta Therapeutics: Commercial-stage antibiotics company with products including vabomere and Baxdela, providing relevant comparability on the commercial economics and stewardship-driven pricing pressures facing Fedora's pipeline assets.
• Tetraphase Biosciences: Developed eravacycline, a novel fluorocycline antibiotic approved for cIAI and cUTI, and was acquired by La Jolla Pharmaceutical Company. Directly comparable as a small-cap antibiotics developer targeting the same ESKAPE-related indications as Fedora's pipeline.

Broad incumbents

• Wockhardt: India-headquartered pharmaceutical company with a notable antibiotics pipeline including beta-lactamase inhibitor combinations (e.g., WCK 5222, cefepime-zidebactam). Comparable as a broader antibiotics developer pursuing similar Gram-negative resistance indications.
• Meiji Seika Pharma: Japanese pharmaceutical company developing and commercializing Fedora's nacubactam and operating a broader antibiotics portfolio including carbapenems. Relevant as both Fedora's commercial partner and as a broader antibiotics peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pg/Fedora-Pharmaceuticals-Inc-174353066045448
• LinkedInlinkedin.com/company/fedorapharma
• Xx.com/FedoraPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fedora Pharmaceuticals